Aztreonam/avibactam

Add links
Source: Wikipedia, the free encyclopedia.

Aztreonam/avibactam
Combination of
β-lactam antibiotic
Avibactamβ-Lactamase inhibitor
Clinical data
Trade namesEmblaveo
ATC code
  • None
Legal status
Legal status

Aztreonam/avibactam, sold under the brand name Emblaveo, is a combination of

Gram-negative infections.[1][2][3][4] Drug resistance to the combination has been reported.[5]

The combination was approved for medical use in the European Union in April 2024.[1][6]

Medical uses

Aztreonam/avibactam is

indicated for the treatment of complicated intra-abdominal infection; hospital-acquired pneumonia, including ventilator-associated pneumonia; or complicated urinary tract infection, including pyelonephritis.[1] It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.[1]

Society and culture

Legal status

In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emblaveo, intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms in people with limited treatment options.[7] The applicant for this medicinal product is Pfizer Europe MA EEIG.[7] The combination was approved for medical use in the European Union in April 2024.[1]

References

  1. ^ a b c d e f "Emblaveo Product information". Union Register of medicinal products. 22 April 2024. Retrieved 22 April 2024.
  2. ^ "Pipeline". AbbVie. Archived from the original on 25 November 2023. Retrieved 25 November 2023.
  3. PMID 36968952
    .
  4. S2CID 257428399
    .
  5. S2CID 237268078
    .
  6. ^ "European Commission Approves Pfizer's Emblaveo for Patients with Multidrug-Resistant Infections and Limited Treatment Options". Pfizer (Press release). 22 April 2024. Retrieved 22 April 2024.
  7. ^ a b "Emblaveo EPAR". European Medicines Agency. 21 March 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Aztreonam/avibactam&oldid=1220278694"